{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:35:14Z","timestamp":1790922914499,"version":"4.1.0"},"reference-count":35,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Public Health Surveill"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Pre-exposure prophylaxis (PrEP) programs have been implemented in multiple countries. Evidence from clinical trials and cohort studies has proven the safety and effectiveness of PrEP. However, minimizing drug-related adverse effects and cost should be primarily considered in PrEP. Most trials used tenofovir combined with emtricitabine as the intervention; yet, the use of tenofovir disoproxil fumarate (TDF) (ie, Tenofovir) alone has not been thoroughly evaluated. Furthermore, the medication regimen in most trials was used every day, with a few studies proposing an optimal medication regimen for PrEP.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study was designed to systematically evaluate the preventive efficacy and safety profile of TDF-based PrEP in the Chinese population. We also aimed to explore medication compliance, changes in sexual behavior, and hazard factors of HIV infection.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a pragmatic randomized controlled trial (RCT) to evaluate the effectiveness and safety of TDF for HIV PrEP. Participants were randomly assigned (1:1:1) to a time-driven group (TDF 300 mg administered orally once daily), an event-driven group (TDF 300 mg administered orally 24 to 48 h before sexual activity and 2 hours after sexual activity, not exceeding 300 mg within 24 h), or an untreated control group. The primary outcomes were the effectiveness and safety of TDF during periods of PrEP use. Secondary outcomes focused on the effectiveness of TDF among participants with good compliance during PrEP use. Tertiary outcomes included the risk factors of HIV infection and behavioral changes from PrEP initiation to the last visit. For ethical reasons, all participants received condoms and health education. This study was registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-13003849).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1914 participants underwent randomization. During the follow-up of 3513.5 person-years from June 2013 to May 2016, HIV seroconversion was observed in 30 persons (2.02 per 100 person-years) in the time-driven group (time-driven vs control group: hazard ratio [HR] 0.93, 95% CI 058\u20101.51;\n P<\/jats:italic>\n =.78), 35 (1.73 per 100 person-years) in the event-driven group (event-driven group vs control group: HR 0.83, 95% CI 0.52\u20101.31;\n P<\/jats:italic>\n =.42), and 37 (2.06 per 100 person-years) in the control group. Post hoc analysis showed that participants with good medication compliance reduced their HIV infection risk by 53% (\n P<\/jats:italic>\n =.01) and event-driven medication with good compliance reduced the risk by 62% (\n P<\/jats:italic>\n =.009). We recorded no severe adverse events during the trial. For tertiary outcomes, low medication compliance, sexual role, no condom use, and more number of sexual partners remained significantly associated with HIV risk.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The TDF-based PrEP is ineffective without good adherence. However, when medication compliance is achieved, event-driven dosing is recommended as an optimal PrEP regimen.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/71494","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T21:21:31Z","timestamp":1755724891000},"page":"e71494-e71494","source":"Crossref","is-referenced-by-count":1,"title":["Tenofovir to Prevent HIV Infection in Western China: Pragmatic Randomized Controlled Trial"],"prefix":"10.2196","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-339X","authenticated-orcid":false,"given":"Yi","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4584-938X","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-8025","authenticated-orcid":false,"given":"Bin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3328-3153","authenticated-orcid":false,"given":"Aizhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-029X","authenticated-orcid":false,"given":"Jianghong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-5124","authenticated-orcid":false,"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-9738","authenticated-orcid":false,"given":"Juying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5560-4109","authenticated-orcid":false,"given":"Huarui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9553-7419","authenticated-orcid":false,"given":"Shihan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8035-1841","authenticated-orcid":false,"given":"Xiaoni","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-7423","authenticated-orcid":false,"given":"Ailong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"11","key":"R1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1089\/apc.2024.0172","article-title":"\u201cAIDS at a Crossroads:\u201d Highlights from the 2024 UNAIDS Report","volume":"38","author":"Laurence","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"R2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306642","article-title":"Spatiotemporal analysis of seasonal trends in land surface temperature within the distribution range of Moringa peregrina (Forssk.) in Southern and Southeastern Iran","volume":"19","author":"Piri Sahragard","journal-title":"PLoS ONE"},{"issue":"48","key":"R3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.46234\/ccdcw2024.251","article-title":"Evolution of HIV epidemic and emerging challenges - China, 1989-2023","volume":"6","author":"Cai","journal-title":"China CDC Wkly"},{"issue":"10013","key":"R4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","journal-title":"Lancet"},{"issue":"7","key":"R5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/sextrans-2013-051121","article-title":"WHO guidelines for HIV\/STI prevention and care among MSM and transgender people: implications for policy and practice","volume":"89","author":"Cohen","journal-title":"Sex Transm Infect"},{"issue":"8","key":"R6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S1473-3099(22)00175-X","article-title":"Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data","volume":"22","author":"Traeger","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"R7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11904-020-00523-0","article-title":"Implementation of universal HIV testing and treatment to reduce HIV incidence in Botswana: the Ya Tsie study","volume":"17","author":"Lockman","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.eururo.2007.04.090","article-title":"Re: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial","volume":"52","author":"Weidner","journal-title":"Eur Urol"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1186\/s12889-018-6178-y","article-title":"The effect of HIV educational interventions on HIV-related knowledge, condom use, and HIV incidence in sub-Saharan Africa: a systematic review and meta-analysis","volume":"18","author":"Faust","journal-title":"BMC Public Health"},{"issue":"2","key":"R10","doi-asserted-by":"publisher","DOI":"10.1177\/13596535211067589","article-title":"Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis","volume":"27","author":"Abdool Karim","journal-title":"Antivir Ther (Lond)"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","article-title":"Primary HIV-1 infection in users of pre-exposure prophylaxis","volume":"8","author":"Ambrosioni","journal-title":"Lancet HIV"},{"issue":"5","key":"R12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0022-5347(11)60198-5","article-title":"Re.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"185","author":"Berger","journal-title":"J Urol"},{"issue":"12","key":"R13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17134","article-title":"Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis","volume":"2","author":"Ong","journal-title":"JAMA Netw Open"},{"issue":"11","key":"R14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/jama.2024.0464","article-title":"HIV preexposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate among cisgender women","volume":"331","author":"Marrazzo","journal-title":"JAMA"},{"issue":"8","key":"R15","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","article-title":"Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study","volume":"9","author":"Molina","journal-title":"Lancet HIV"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104648","article-title":"Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial","volume":"93","author":"Herrera","journal-title":"EBioMedicine"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","first-page":"101634","DOI":"10.1016\/j.joi.2024.101634","article-title":"Integration vs segregation: network analysis of interdisciplinarity in funded and unfunded research on infectious diseases","volume":"19","author":"Du","journal-title":"J Informetr"},{"issue":"11","key":"R18","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S2352-3018(18)30215-7","article-title":"Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study","volume":"5","author":"Grulich","journal-title":"Lancet HIV"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2468-2667(18)30236-6","article-title":"The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study","volume":"4","author":"B\u00f3rquez","journal-title":"Lancet Public Health"},{"issue":"11","key":"R20","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2352-3018(24)00239-X","article-title":"Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis","volume":"11","author":"Wu","journal-title":"Lancet HIV"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5011","article-title":"Recent advances in pre-exposure prophylaxis for HIV","volume":"359","author":"Desai","journal-title":"BMJ"},{"issue":"7","key":"R22","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2352-3018(22)00126-6","article-title":"Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial","volume":"9","author":"Ngure","journal-title":"Lancet HIV"},{"issue":"9","key":"R23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","journal-title":"Clin Pharmacokinet"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-385","article-title":"Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China","volume":"12","author":"Wu","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/QAI.0000000000002640","article-title":"Changes in sexual behavior, PrEP adherence, and access to sexual health services because of the COVID-19 pandemic among a cohort of PrEP-using MSM in the South","volume":"87","author":"Pampati","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"23","key":"R26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-Demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","journal-title":"N Engl J Med"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services","volume":"176","author":"Liu","journal-title":"JAMA Intern Med"},{"issue":"8","key":"R28","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S2352-3018(21)00074-6","article-title":"Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study","volume":"8","author":"Grulich","journal-title":"Lancet HIV"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100541","article-title":"PrEP uptake and adherence in relation to HIV-1 incidence among Kenyan men who have sex with men","volume":"26","author":"Wahome","journal-title":"EClinicalMedicine"},{"issue":"2","key":"R30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the hiv-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","journal-title":"JAMA"},{"issue":"5","key":"R31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/cid\/ciy182","article-title":"Effects of pre-exposure prophylaxis for the prevention of Human Immunodeficiency Virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis","volume":"67","author":"Traeger","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R32","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v21i1.1157","article-title":"Sexual risk compensation following voluntary medical male circumcision: results from a prospective cohort study amongst human immunodeficiency virus-negative adult men in Botswana","volume":"21","author":"Spees","journal-title":"South Afr J HIV Med"},{"issue":"18","key":"R33","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1097\/01.aids.0000433237.63560.20","article-title":"Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models","volume":"27","author":"van de Vijver","journal-title":"AIDS"},{"issue":"10","key":"R34","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1093\/jac\/dkab253","article-title":"Estimated pill intake with on-demand PrEP with oral TDF\/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial","volume":"76","author":"Goldwirt","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4559-1","article-title":"The prevalence of HIV among MSM in China: a large-scale systematic analysis","volume":"19","author":"Dong","journal-title":"BMC Infect Dis"}],"container-title":["JMIR Public Health and Surveillance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publichealth.jmir.org\/2025\/1\/e71494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:00:53Z","timestamp":1782842453000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealth.jmir.org\/2025\/1\/e71494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2196\/71494","relation":{},"ISSN":["2369-2960"],"issn-type":[{"value":"2369-2960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"v11i11e71494"}}